The estimated Net Worth of Capital Management Company,... is at least 45.4 百万$ dollars as of 20 June 2023. Capital Company owns over 4,760,000 units of Zentalis Pharmaceuticals, Llc stock worth over 45,369,912$ and over the last few years Capital sold ZNTL stock worth over 0$.
Sign up
Capital Company ZNTL stock SEC Form 4 insiders trading
Capital has made over 1 trades of the Zentalis Pharmaceuticals, Llc stock since 2023, according to the Form 4 filled with the SEC. Most recently Capital bought 4,760,000 units of ZNTL stock worth 107,861,600$ on 20 June 2023.
The largest trade Capital's ever made was buying 4,760,000 units of Zentalis Pharmaceuticals, Llc stock on 20 June 2023 worth over 107,861,600$. On average, Capital trades about 4,760,000 units every 0 days since 2023. As of 20 June 2023 Capital still owns at least 13,959,973 units of Zentalis Pharmaceuticals, Llc stock.
You can see the complete history of Capital Company stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Zentalis Pharmaceuticals, Llc
Over the last 5 years, insiders at Zentalis Pharmaceuticals, Llc have traded over 106,453,887$ worth of Zentalis Pharmaceuticals, Llc stock and bought 5,536,611 units worth 121,990,782$ . The most active insiders traders include Global Investors Lp Viking ...、Capital Management Company,...、Anthony Y Sun. On average, Zentalis Pharmaceuticals, Llc executives and independent directors trade stock every 11 days with the average trade being worth of 188,516$. The most recent stock trade was executed by Cam Gallagher on 31 May 2024, trading 9,597 units of ZNTL stock currently worth 114,972$.
What does Zentalis Pharmaceuticals, Llc do?
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
What does Zentalis Pharmaceuticals, Llc's logo look like?
Complete history of Capital Company stock trades at Zentalis Pharmaceuticals, Llc
Zentalis Pharmaceuticals, Llc executives and stock owners
Zentalis Pharmaceuticals, Llc executives and other stock owners filed with the SEC include:
-
Dr. Anthony Y. Sun M.D.,
Pres, CEO & Exec. Chairman -
Dr. Kevin D. Bunker Ph.D.,
Chief Operating Officer -
Alexis M. Pinto J.D.,
Chief Legal Officer & Sec. -
Dr. Meena Rao Ph.D.,
Sr. VP of Regulatory Affairs & Quality Assurance -
Dr. Peter Huang Ph.D.,
Sr. VP of Discovery Research -
Dr. Dimitris Voliotis M.D.,
Sr. VP of Clinical Devel. -
Melissa B. Epperly M.B.A.,
CFO & Treasurer -
Capital Management Company,...,
-
Andrea Paul,
Chief Legal Officer -
Luke Nathaniel Walker,
Director -
Dimitris Voliotis,
SVP, Clinical Development -
Anthony Y Sun,
President & CEO -
David Michael Johnson,
Director -
Melissa B, Epperly,
Chief Financial Officer -
Alexis Pinto,
Chief Legal Officer -
Equity, Llc Recurium,
10% owner -
Jan Skvarka,
Director -
Enoch Kariuki,
Director -
Carrie Brownstein,
Chief Medical Officer -
Kevin D. Bunker,
Chief Scientific Officer -
Iris Roth,
Chief Operating Officer -
Kimberly Blackwell,
Chief Executive Officer -
Cam Gallagher,
President, Interim CFO -
Mark Lackner,
Chief Scientific Officer -
Diana Hausman,
Chief Medical Officer